CSS LLC’s Cardiff Oncology CRDF Stock Holding History

CSS LLC’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,200	Closed	-$25K	–	1187
2021 Q4	$25K	Hold	4,200	–	–	﹤0.01%	1157
2021 Q3	$28K	Buy	+4,200	New	+$26.4K	﹤0.01%	1112

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

CSS LLC's CRDF Position: Q4 2022 in Review

CSS LLC sold out of Cardiff Oncology (CRDF) in Q4 2022, closing a stake of 35,920 shares — an estimated $55K sold.

CSS LLC first reported a position in CRDF in Q4 2020 and held it in 7 quarters. The position peaked at $224K in Q2 2021. 60 funds tracked by Wall St. Rank hold CRDF as of Q4 2022.

CSS LLC reported no remaining Cardiff Oncology position as of Q4 2022 after selling out during the quarter.
CSS LLC sold 35,920 Cardiff Oncology shares in Q4 2022, an estimated $55K.
CSS LLC first reported a position in Cardiff Oncology in Q4 2020 and held it in 7 quarters.
CSS LLC's Cardiff Oncology position peaked at $224K in Q2 2021.
60 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.